Connor, Clark & Lunn Investment Management (CC&L)’s aTyr Pharma ATYR Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-20,994	Closed	-$15.1K	–	1821
2025 Q3	$15.1K	Buy	+20,994	New	+$95.1K	﹤0.01%	1475
2018 Q2	–	Sell	-3,150	Closed	-$117K	–	1114
2018 Q1	$117K	Hold	3,150	–	–	﹤0.01%	685
2017 Q4	$154K	Hold	3,150	–	–	﹤0.01%	737
2017 Q3	$223K	Hold	3,150	–	–	﹤0.01%	745
2017 Q2	$152K	Buy	3,150 +71	+2%	+$3.32K	﹤0.01%	766
2017 Q1	$151K	Buy	3,079 +350	+13%	+$16K	﹤0.01%	825
2016 Q4	$82K	Buy	2,729 +186	+7%	+$7.63K	﹤0.01%	846
2016 Q3	$113K	Buy	2,543 +1,693	+199%	+$73.2K	﹤0.01%	770
2016 Q2	$33K	Buy	+850	New	+$39.5K	﹤0.01%	845

Other funds holding ATYR

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s ATYR Position: Q4 2025 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of aTyr Pharma (ATYR) in Q4 2025, closing a stake of 20,994 shares — an estimated $15.1K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ATYR in Q2 2016 and held it in 9 quarters. The position peaked at $223K in Q3 2017. 84 funds tracked by Wall St. Rank hold ATYR as of Q4 2025.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining aTyr Pharma position as of Q4 2025 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 20,994 aTyr Pharma shares in Q4 2025, an estimated $15.1K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in aTyr Pharma in Q2 2016 and held it in 9 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s aTyr Pharma position peaked at $223K in Q3 2017.
84 funds tracked by Wall St. Rank held aTyr Pharma as of Q4 2025.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2025, filed 10 Feb 2026.